Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Perflubutane→

Perflubutane PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
355-25-9
Molecular formula
C4F10
Molecular weight
238.03 g/mol
Drug class
Diagnostic ultrasound contrast agentperfluorobutane gas-filled microbubble
Mechanism of action
Perflubutane microbubbles circulate intravascularly and strongly scatter ultrasound waves, enhancing vascular and tissue perfusion signals. In the liver, the stabilised microbubbles are taken up by Kupffer cells, allowing vascular and postvascular (Kupffer) phase imaging.
Indications / reported uses
  • Contrast-enhanced ultrasound for evaluation of focal liver lesions in countries where Sonazoid is authorised.
  • In Japan, also used for selected breast-lesion ultrasound imaging under the relevant product authorisation. The diagnostic agent is the formulated perflubutane microbubble product, not the gas alone.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC7446696/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC11499413/ · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Diagnostic ultrasound contrast agent; perfluorobutane gas-filled microbubble

Mechanism of action

Perflubutane microbubbles circulate intravascularly and strongly scatter ultrasound waves, enhancing vascular and tissue perfusion signals. In the liver, the stabilised microbubbles are taken up by Kupffer cells, allowing vascular and postvascular (Kupffer) phase imaging.

General use cases

  • Contrast-enhanced ultrasound for evaluation of focal liver lesions in countries where Sonazoid is authorised.
  • In Japan, also used for selected breast-lesion ultrasound imaging under the relevant product authorisation. The diagnostic agent is the formulated perflubutane microbubble product, not the gas alone.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Perflubutane PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Perflubutane Permitted Daily Exposure (PDE) report (the Perflubutane PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Perflubutane Occupational Exposure Limit (OEL) report (the Perflubutane OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.